Key Highlights
- Company actively courting oncology-focused pharmaceutical partnerships
- Phase 2 protocol for SER-155 already finalized with FDA
- Move follows funding pause disclosed in February 2026
- Positive Phase 1b data adds leverage to partnership discussions
- SER-155 targets immune-mediated enterocolitis in cancer patients
Seres Therapeutics is turning to the partnership market to secure the next phase of development for SER-155, its live biotherapeutic candidate for immune-mediated enterocolitis, as the company works around a previously disclosed funding constraint that paused further internal investment in the program. The strategy reflects a common playbook for capital-constrained biotechs holding a clinically validated but resource-intensive asset: seek a partner with deeper pockets and commercial infrastructure rather than attempting to fund late-stage development alone.
Seres enters those discussions with two important assets in hand. First, the company and the FDA have already finalized the protocol for a Phase 2 trial, removing a significant source of regulatory uncertainty that would otherwise complicate partnership negotiations. Second, freshly reported Phase 1b data from a Memorial Sloan Kettering-led study showed an 80% immunosuppression-free clinical response rate by day 15, with a third of patients achieving full remission — a dataset strong enough to meaningfully improve Seres's negotiating position relative to earlier-stage or less-validated partnership targets.
The oncology focus of the search is deliberate. Immune-mediated enterocolitis most commonly arises as a side effect of cancer immunotherapy, particularly checkpoint inhibitors, meaning the most natural commercial partners are pharmaceutical companies with existing oncology franchises who stand to benefit from a therapy that helps patients remain on immunotherapy for longer. For a prospective partner, licensing or co-developing SER-155 could function almost as a companion therapy to their own checkpoint inhibitor portfolio, improving the overall tolerability profile of drugs already generating substantial revenue.
Whether Seres can convert its favorable clinical data and finalized regulatory pathway into a partnership on attractive terms remains an open question, and one that will likely determine both the near-term trajectory of the stock and the ultimate fate of a program that has already cleared some of biotech's most difficult hurdles.
Why is Seres seeking a partner rather than funding SER-155 independently?
The company disclosed a funding pause on the program in February and is now seeking a well-capitalized oncology partner to advance the already FDA-finalized Phase 2 protocol.
What makes oncology-focused pharmaceutical companies natural partners?
SER-155 treats a complication of cancer immunotherapy, making companies with existing checkpoint inhibitor franchises well-positioned to benefit from a therapy that helps patients stay on treatment longer.
This article is for informational purposes and does not constitute investment advice.






Please wait processing your request...